<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title>Frontiers in Endocrinology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Endocrinol.</abbrev-journal-title>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fendo.2025.1643543</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A systematic review and evidence assessment of monogenic gene-disease relationships in human male infertility</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Qian</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/3127064/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Huifang</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/1198819/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Jiali</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/2659694/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Hui</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/3022620/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ma</surname>
<given-names>Yujin</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2843060/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jiang</surname>
<given-names>Hongwei</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1893826/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Luoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology</institution>, <addr-line>Luoyang</addr-line>,&#xa0;<country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1185436/overview">Mohammad Ishraq Zafar</ext-link>, Zhejiang University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1464926/overview">Kun Li</ext-link>, Hangzhou Medical College, Hangzhou, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2984384/overview">Eren Er</ext-link>, Izmir City Hospital, T&#xfc;rkiye</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Hongwei Jiang, <email xlink:href="mailto:jianghw@haust.edu.cn">jianghw@haust.edu.cn</email>; Yujin Ma, <email xlink:href="mailto:mayujin126@126.com">mayujin126@126.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="ecorrected">
<day>12</day>
<month>09</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1643543</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>06</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>08</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Zhao, Peng, Chen, Zhang, Ma and Jiang.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Zhao, Peng, Chen, Zhang, Ma and Jiang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Genetic factors play a significant role in human male infertility, with about 4% of infertile men currently identified with genetic reasons, yet most (60&#x2013;70%) still lack a definitive diagnosis and remain unexplained. Similar to other medical fields, the advent of next-generation sequencing (NGS) has resulted in the discovery of a growing array of genetic variations in infertility issues affecting both genders. With the rising count of newly discovered genes, precise diagnoses are now possible for cases of male infertility that were once considered idiopathic. Nonetheless, substantial proof supporting the gene-disease relationships (GDR) remains absent in numerous instances.</p>
</sec>
<sec>
<title>Objective and rationale</title>
<p>The year 2019 and 2021 saw the release and revision of the standardized clinical validity evaluation for monogenic reasons behind male infertility. In this report, we offer an extensive review to methodically assess all existing data (spanning from 1 Jan, 2020, to 24 Sep, 2024) regarding the singular causes of either isolated or syndromic male infertility, hormonal imbalances, or reproductive irregularities in male reproductive organs.</p>
</sec>
<sec>
<title>Search method</title>
<p>The PRISMA protocols were utilized to gather comprehensive data from PubMed and Web of Science regarding the genetics of human male infertility and disorders of sex development (DSD) resulting in infertility, spanning from 1 January 2020 to 24 September 2024. The pathologies examined encompass both isolated infertility and syndromic male infertility, along with disorders of the endocrine and reproductive systems. A standardized scoring system was used to evaluate whether pathogenic variations in a particular gene lead to a recognized phenotype. Each GDR received a conclusive rating, ranging from no evidence to definitive.</p>
</sec>
<sec>
<title>Outcomes</title>
<p>Out of 19885 identified and screened publications, 229 were chosen for gene and variant analysis. Our research has pinpointed 191 genes and confirmed 191 GDRs, encompassing all documented single-gene reasons for male infertility and DSD. Additionally, our research pinpointed 100 genes with at least a moderate connection to male infertility or atypical genitourinary development traits. The study did not take into account associated genetic risk factor(s) or oligogenic/polygenic causes of male infertility.</p>
</sec>
<sec>
<title>Systematic review registration</title>
<p>
<uri xlink:href="http://www.crd.york.ac.uk/PROSPERO">http://www.crd.york.ac.uk/PROSPERO</uri>, identifier CRD42024593082.</p>
</sec>
</abstract>
<kwd-group>
<kwd>male infertility</kwd>
<kwd>monogenic</kwd>
<kwd>gene-disease relationship</kwd>
<kwd>next-generation sequencing</kwd>
<kwd>systematic review</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="45"/>
<page-count count="15"/>
<word-count count="7724"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Reproduction</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Infertility is a global health issue, with approximately 17.5% of the adult population (about 1 in 6 worldwide) suffering from infertility, and many people are affected by it during their lifetime (<xref ref-type="bibr" rid="B1">1</xref>), according to a new World Health Organization (WHO) report released today. Male infertility is the full or partial cause of infertility in 20-70% of couples (<xref ref-type="bibr" rid="B2">2</xref>), and normal fertility in the female partner may compensate for reduced fertility in the male partner. And low fertility in a male partner may hinder or completely eliminate conception, regardless of the fertility of the female partner. Male infertility is a complex, multifactorial pathological condition with a highly heterogeneous phenotype, ranging from complete absence of sperm in the testicles to significant changes in sperm quality, in which genetic factors play a major role (<xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>Karyotype analysis (KA), azoospermia factor (AZF) microdeletion screening, and candidate gene mutation screening are part of the diagnostic examination for male infertility (<xref ref-type="bibr" rid="B4">4</xref>). A persistent challenge in andrological genetics lies in the lack of standardized diagnostic protocols for male infertility, where even essential evaluations&#x2014;including cytogenetic karyotyping and Y chromosome microdeletion analysis (AZFa, AZFb, AZFc regions)&#x2014;exhibit significant inter-laboratory variability in clinical implementation. While NGS advancements have revolutionized genetic diagnostics through high-throughput platforms enabling comprehensive whole-exome sequencing (WES) and whole-genome sequencing (WGS), this technological progress has not yet translated into consensus guidelines for systematic application in male infertility investigations. Over the past 5&#x2013;10 years, the application of NGS technology in the field of male infertility has risen rapidly, helping to translate research findings into clinical practice as clinical cohorts grow. To aid this knowledge feedback, the effectiveness of screening individual genes and their relevance to certain types of infertility need to be clearly stated.</p>
<p>The Clinical Genome Resource (ClinGen) has established a comprehensive system for evaluating the clinical credibility of gene-disease connections (<xref ref-type="bibr" rid="B5">5</xref>). Another more streamlined and practical form of this model has been released recently, simplifying the evaluation of gene-disease linkages in clinical settings (<xref ref-type="bibr" rid="B6">6</xref>). The simplified system achieves rapid clinical decision-making by consolidating evidence categories, compressing evidence dimensions, and eliminating time validation requirements. While previous efforts, such as the comprehensive 2021 review by Houston et&#xa0;al., have laid the foundation for systematic evaluation of GDRs in male infertility (<xref ref-type="bibr" rid="B7">7</xref>), the accelerating pace of discovery and emergence of novel diagnostic tools necessitate a more updated and forward-looking synthesis. Our work aims to fulfill this unmet need by integrating recent evidence, expanding phenotype coverage. We summarized existing knowledge on male infertility and DSD between January 1, 2020 and September 24, 2024. We used the standardized clinical validity evaluation procedure of Smith et&#xa0;al. (<xref ref-type="bibr" rid="B6">6</xref>) to evaluate the clinical validity of 191 pathogenic genes involved in male infertility. This analysis allowed us to objectively classify the evidence for the involvement of genes in male infertility as non-existing, limited, moderate, strong or definitive. Findings from this study could be beneficial for research and diagnostic purposes, such as creating diagnostic gene panels, and potentially bolster genetic studies in male infertility.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Search strategy and study selection</title>
<p>The PRISMA guidelines to identify, select, appraise and synthesize studies were followed as well as for design and reporting (<xref ref-type="bibr" rid="B8">8</xref>). A literature search was performed as described in Brendan J. Houston et&#xa0;al. (<xref ref-type="bibr" rid="B7">7</xref>) to identify articles reporting on monogenic causes of male infertility or male reproductive system anomalies in PubMed (<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</ext-link>),Web of Science (WoS, <ext-link ext-link-type="uri" xlink:href="https://www.webofknowledge.com">https://www.webofknowledge.com</ext-link>),Embase (<ext-link ext-link-type="uri" xlink:href="https://www.embase.com">https://www.embase.com</ext-link>),Ovid MEDLINE (<ext-link ext-link-type="uri" xlink:href="https://www.ovid.com/">https://www.ovid.com/</ext-link>),Scopus (<ext-link ext-link-type="uri" xlink:href="https://www.scopus.com">https://www.scopus.com</ext-link>) between 1 Jan, 2020, and 24 Sep, 2024. The search was confined to the initial research on human subjects featured in peer-reviewed English journals. The full electronic search strategy (including search terms, MeSH headings, and database-specific filters for PubMed, Web of Science, Embase, Ovid MEDLINE, Scopus) and the inclusion/exclusion criteria for screening titles, abstracts, and full texts are detailed in <xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Table S1</bold>
</xref>. The relevance of titles, abstracts, and the entire text was assessed based on established criteria for inclusion and exclusion. Assessment of whether the articles met the inclusion or exclusion criteria was performed by two independent reviewers. This study, along with its associated search methodology, was recorded in the PROSPERO registry (<ext-link ext-link-type="uri" xlink:href="http://www.crd.york.ac.uk/PROSPERO">http://www.crd.york.ac.uk/PROSPERO</ext-link>) under the identifier PROSPERO 2024: CRD42024593082.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Data selection and scoring of gene-disease relationships- extraction process</title>
<p>Genes and genetic variations linked to male infertility or anomalies in the male reproductive system were isolated from the chosen complete texts. Each GDR&#x2019;s clinical legitimacy was assessed using a modified version of Smith et&#xa0;al.&#x2019;s standardized scoring method (<xref ref-type="bibr" rid="B6">6</xref>).Two evaluators, chosen at random from a group of six authors (QZ and HFP), utilized a uniform evaluation framework to identify gene names, genetic inheritance trends, patient characteristics, discovery techniques (sequencing method), label variants, and examine both functional and clinical data. Reviewers were prohibited from rating any published GDRs to prevent partiality in assessing gene-disease and potential conflicts of interest. Under this evaluation method, each GDR received a conclusive score: no evidence (&lt;3 points), limited (3&#x2013;8 points), moderate (9&#x2013;12 points), strong (13&#x2013;15 points) or definitive (&gt;15 points). Following separate evaluations, each reviewer&#x2019;s individual scores (pertaining to each GDR) were analyzed, and any scoring discrepancies (&gt;1 point variance or final classification discrepancy) were resolved by the designated reviewers. In cases where consensus was elusive, these were deliberated with all reviewers who were not in conflict. GDRs classified as moderate or above were confidently associated with human male infertility, with all study findings compiled in <xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Table S2</bold>
</xref>.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Search strategy and study selection</title>
<p>Our research approach was designed to uncover every publication related to the genetic aspects of male infertility, encompassing syndromes impacting the endocrine system, DSD and genitourinary anomalies. We performed a literature search using terms related to &#x2018;male infertility&#x2019; in combination with keywords related to the word &#x2018;genetics&#x2019; in MEDLINE-PubMed and used the same inclusion and exclusion criteria as described previously (<xref ref-type="bibr" rid="B7">7</xref>). We identified 20215 articles, of which 5589 were in PubMed,331 were in Embase,1439 were in Ovid MEDLINE,40 were in scopus and 12816 unique to WoS (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Out of these, 557 abstracts were selected excluding publications exclusively on female infertility as well as studies on nonhuman species, pediatric cases, reviews and irrelevant topics. Out of these abstracts, 229 papers were selected for full text screening. Through a rigorous systematic review process, 229 peer-reviewed articles met the inclusion criteria for subsequent genomic data extraction. Subsequent analysis revealed 191 distinct genes of interest, which were subsequently evaluated using our novel GDR scoring system. The study selection methodology is visually summarized in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>, which presents a PRISMA-compliant flowchart detailing the four-stage screening process: identification, screening, eligibility assessment, and final inclusion.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>PRISMA flowchart of search and assessment process. (AR, autosomal recessive; AD, autosomal dominant; XL, X-linked; YL, Y-linked; MT, Mitochondrial Inheritance; NA, Not Available).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fendo-16-1643543-g001.tif">
<alt-text content-type="machine-generated">Flowchart depicting the identification process of studies for a review. The process includes identification, screening, and inclusion stages. Initially, 19,885 records were identified. After removing 6,687 duplicates, 13,528 underwent screening. Exclusions were due to language, non-human studies, and irrelevant topics. After full-text screening of 557 studies, 229 were included. Tables show evidence assessment of gene-disease relationships across categories: AR, AD, XL, YL, MT, and NA, with varying levels from definitive to no evidence.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Evaluation of the gene-disease relationship</title>
<p>Two separate evaluators assessed the robustness and thoroughness of all data pertaining to the GDRs, employing a uniform scoring technique. The given score served to determine the clinical credibility of each GDR, which was classified into categories like no evidence, limited, moderate, strong, or definitive. The assessment included the quality of the experiment, details of patient phenotypes, gene expression-based functional data, and research on animal and cell models with <italic>in vitro</italic> and <italic>in vivo</italic> loss of function. The reclassification of variants adhered to the broadly recognized standards of the American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP), followed by their recording in spreadsheet formats for each GDR.</p>
<p>The clinical validity of 191 GDRs was evaluated and 41 were classified as showing definitive evidence, 25 as strong evidence, 34 as moderate evidence, 82 as limited evidence and 9 as no evidence (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Overall, 191 individual GDRs described in these 229 publications were investigated, of which 85 were newly identified and 106 were re-evaluated with our updated assessment criteria in order to incorporate any additional supporting evidence.</p>
<p>Of the 85 newly identified GDRs, 26 were classified as having moderate or higher evidence (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) and 53 as having limited evidence. After classifying the existing GDRs where new evidence has been published, and using our updated scoring criteria to rate GDRs that were previously believed to be related to male infertility, 50 reports have improved since 2020 (<xref ref-type="supplementary-material" rid="SF3">
<bold>Supplementary Table S3</bold>
</xref>). The 56 scores were unchanged from the previous assessment, as no (or insufficient) new evidence was released during the search (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Table S2</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Evidence quality for 26 new genes with moderate-to-definitive evidence in male infertility.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Gene</th>
<th valign="middle" align="left">Disorder</th>
<th valign="middle" align="left">Location</th>
<th valign="middle" align="left">OMIM ID</th>
<th valign="middle" align="left">Inheritance</th>
<th valign="middle" align="left">Study count</th>
<th valign="middle" align="left">Validation</th>
<th valign="middle" align="left">Score in 2024</th>
<th valign="middle" align="left">Conclusion in 2024</th>
<th valign="middle" align="left">Change 2020 to 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">
<italic>ACTL9</italic>
</td>
<td valign="middle" align="left">Fertilization failure</td>
<td valign="middle" align="left">19p13.2</td>
<td valign="middle" align="left">619258</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>ATG4D</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">19p13.2</td>
<td valign="middle" align="left">611340</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>CCDC151</italic>
</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">19p13.2</td>
<td valign="middle" align="left">616037</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>CCDC34</italic>
</td>
<td valign="middle" align="left">Oligoasthenoteratozoospermia</td>
<td valign="middle" align="left">11p14.1</td>
<td valign="middle" align="left">620084</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>CFAP58</italic>
</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">10q25.1</td>
<td valign="middle" align="left">619144</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>CFAP61</italic>
</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">20p11.23</td>
<td valign="middle" align="left">620409</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>DNAAF1</italic>
</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">16q24.1</td>
<td valign="middle" align="left">613193</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>DNAH10</italic>
</td>
<td valign="middle" align="left">asthenoteratozoospermia</td>
<td valign="middle" align="left">12q24.31</td>
<td valign="middle" align="left">619515</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>DNAH11</italic>
</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">7p15.3</td>
<td valign="middle" align="left">611884</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>DNAH7</italic>
</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">2q32.3</td>
<td valign="middle" align="left">620356</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>DNAH8</italic>
</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">6p21.2</td>
<td valign="middle" align="left">619095</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>DNHD1</italic>
</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">11p15.4</td>
<td valign="middle" align="left">619712</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>DRC3</italic>
</td>
<td valign="middle" align="left">asthenozoospermia</td>
<td valign="middle" align="left">17p11.2</td>
<td valign="middle" align="left">NA</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>GCNA</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">Xq13.1</td>
<td valign="middle" align="left">301077</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>IFT140</italic>
</td>
<td valign="middle" align="left">Oligoasthenoteratozoospermia</td>
<td valign="middle" align="left">16p13.3</td>
<td valign="middle" align="left">617781</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>IGSF1</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">Xq26.1</td>
<td valign="middle" align="left">300888</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>LRRC23</italic>
</td>
<td valign="middle" align="left">asthenozoospermia</td>
<td valign="middle" align="left">12p13.31</td>
<td valign="middle" align="left">620848</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>MSH5</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">6p21.33</td>
<td valign="middle" align="left">619937</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>PNLDC1</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">6q25.3</td>
<td valign="middle" align="left">619528</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>RSPH4A</italic>
</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">6q22.1</td>
<td valign="middle" align="left">612649</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>SHOC1</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">9q31.3</td>
<td valign="middle" align="left">619949</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>SLC26A8</italic>
</td>
<td valign="middle" align="left">asthenoteratozoospermia</td>
<td valign="middle" align="left">6p21.31</td>
<td valign="middle" align="left">606766</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>SPATA22</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">17p13.2</td>
<td valign="middle" align="left">621001</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>TERB1</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">16q22.1</td>
<td valign="middle" align="left">619646</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>TKTL1</italic>
</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">Xq28</td>
<td valign="middle" align="left">300044</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">
<italic>TTC12</italic>
</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">11q23.2</td>
<td valign="middle" align="left">618801</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Quality of Evidence is divided into two parts: Study count and Validation. The study counts include Number of unrelated patients, Other Statistical Evidence, and Number publications reporting independent probands. Number of pathogenic variants, with a maximum total score of 12 points. Verification includes Gene Function, Gene Disruption, Model Organism, with a maximum total score of 6 points.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The combination of new and established GDR generated 100 genotypes associated with male infertility or abnormal genitourinary development phenotypes in humans, with moderate or higher evidence. Another 82 GDRs were classified as &#x201c;limited&#x201d; and therefore candidate genes whose dysfunction may lead to male infertility disorder (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Table S2</bold>
</xref>). Our suggestion is that the latter group, characterized by limited evidence, will merit special attention in future years.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Overview of human genes involved in human male infertility</title>
<p>Rooted in the physiological dominance of the hypothalamic-pituitary-gonadal (HPG) axis in regulating male reproductive homeostasis, etiological classifications of infertility stratify pathology into three distinct compartments: pretesticular (endocrine dysregulation), testicular (primary gonadal failure), and post-testicular (obstructive/secretory dysfunction). Through functional annotation of genes with documented involvement in human spermatogenic impairment&#x2014;supported by experimental or clinical evidence&#x2014;we systematically classified these molecular candidates according to their pathophysiological contributions within this tripartite framework to delineate their mechanistic roles across the reproductive continuum.</p>
<p>The findings demonstrate that pre-testicular infertility predominantly manifests as syndromic conditions attributable to endocrine dysfunction, specifically exhibiting deficient sex steroid concentrations and dysregulated gonadotropin secretion. In contrast, post-testicular etiologies primarily involve anatomical obstructions that disrupt normal sperm transit from the testes. A clinically significant obstruction pattern arises from congenital vas deferens agenesis, which may present unilaterally or bilaterally (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Numbers of genes that are at least moderately linked to male infertility or abnormal genitourinary development phenotypes.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Description</th>
<th valign="middle" align="left">AR</th>
<th valign="middle" align="left">AD</th>
<th valign="middle" align="left">XL</th>
<th valign="middle" align="left">YL</th>
<th valign="middle" align="left">Total</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">
<bold>Isolated infertility</bold>
</td>
<td valign="middle" align="left">
<bold>49</bold>
</td>
<td valign="middle" align="left">
<bold>5</bold>
</td>
<td valign="middle" align="left">
<bold>8</bold>
</td>
<td valign="middle" align="left">
<bold>1</bold>
</td>
<td valign="middle" align="left">
<bold>63</bold>
</td>
</tr>
<tr>
<td valign="middle" align="left">Acephalic sperm</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">3</td>
</tr>
<tr>
<td valign="middle" align="left">Globozoospermia</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left">Macrozoospermia</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">1</td>
</tr>
<tr>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">15</td>
</tr>
<tr>
<td valign="middle" align="left">Non-obstructive azoospermia or oligoasthenoteratozoospermia</td>
<td valign="middle" align="left">25</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">37</td>
</tr>
<tr>
<td valign="middle" align="left">Congenital bilateral absence of the vas deferens</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">3</td>
</tr>
<tr>
<td valign="middle" align="left">Fertilization failure</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">3</td>
</tr>
<tr>
<td valign="middle" align="left">
<bold>Syndromic infertility</bold>
</td>
<td valign="middle" align="left">
<bold>18</bold>
</td>
<td valign="middle" align="left">
<bold>1</bold>
</td>
<td valign="middle" align="left">
<bold>1</bold>
</td>
<td valign="middle" align="left">
<bold>0</bold>
</td>
<td valign="middle" align="left">
<bold>21</bold>
</td>
</tr>
<tr>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">18</td>
</tr>
<tr>
<td valign="middle" align="left">Other syndromes</td>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">3</td>
</tr>
<tr>
<td valign="middle" align="left">
<bold>Endocrine disorder/Reproductive system syndrome</bold>
</td>
<td valign="middle" align="left">
<bold>5</bold>
</td>
<td valign="middle" align="left">
<bold>7</bold>
</td>
<td valign="middle" align="left">
<bold>4</bold>
</td>
<td valign="middle" align="left">
<bold>1</bold>
</td>
<td valign="middle" align="left">
<bold>17</bold>
</td>
</tr>
<tr>
<td valign="middle" align="left">Disorders of sexual development</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">9</td>
</tr>
<tr>
<td valign="middle" align="left">Hypogonadotropic hypogonadism</td>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">0</td>
<td valign="middle" align="left">8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AR, autosomal recessive; AD, autosomal dominant; XL, X-linked; YL, Y-linked.</p>
</fn>
<fn>
<p>The meanings of the bold values represent the comprehensive categories of the three types of infertility phenotypes.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The majority of confident GDRs were isolated infertility phenotypes (n=63) in 2020-2024, while a minority were linked to endocrine disorders or reproductive system syndromes (n=17) and syndromic infertility (n=21), including primary ciliary dyskinesia (PCD; <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). The majority of all genes known to cause isolated infertility phenotypes are involved in non-obstructive azoospermia (NOA) or oligoasthenoteratozoospermia (n=37, 58.73% of all 63). Patients with multiple morphological abnormalities of the sperm fagellum (MMAF) phenotypes are also of particular interest. Fifteen genes were confidently associated with MMAF in humans, 5 of which were not reported in previous studies (<xref ref-type="bibr" rid="B7">7</xref>). NGS can diagnose up to 50 percent of MMAF patients, although it represents only a fraction of those with isolated infertility (<xref ref-type="bibr" rid="B9">9</xref>). The majority of all GDRs represented an autosomal recessive inheritance pattern (n=72), while autosomal dominant (n=13), X-linked (n=13) and Y-linked (n=2) inheritance patterns were also reported.</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Novel additions beyond previous reviews</title>
<p>Our study represents a significant advancement beyond the 2021 review by Houston et&#xa0;al., offering both temporal and methodological improvements in the evaluation of GDRs associated with male infertility. Several key novel contributions distinguish our work:</p>
<p>We included 229 peer-reviewed studies published between January 1, 2020, and September 24, 2024, thus expanding the evidence base beyond the time frame covered by Houston et&#xa0;al. (up to 2020). This allowed us to capture newly discovered genes and emerging evidence for previously reported GDRs. In addition to the databases used in prior studies (e.g., PubMed, Web of Science), we integrated additional high-impact sources such as Embase, Scopus and Ovid MEDLINE. This comprehensive search strategy increased the breadth and robustness of the included data. Among the 191 genes evaluated, 85 were newly identified since the prior review, and 26 GDRs demonstrated at least moderate clinical validity (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). These genes, not previously included in the 2021 assessment, reflect the rapid evolution of the field and underscore the importance of continuous evidence synthesis. We re-examined 106 GDRs previously evaluated by Houston et&#xa0;al., applying updated scoring criteria. As a result, 50 GDRs were upgraded in their clinical validity classification based on newly available functional or clinical data. This highlights the value of dynamic reassessment as new evidence accumulates.</p>
<p>Our review reveals a substantial shift in diagnostic methodology, with over 81% of included studies utilizing NGS. This reflects an emerging consensus around the utility of NGS technologies and supports the feasibility of integrating genetic testing into clinical workflows. Together, these innovations provide a substantial update to the current understanding of the genetic architecture of male infertility, reinforcing the need for regular reassessments and integrative methodologies in the era of precision medicine.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>Our study builds upon the foundational work of Houston et&#xa0;al. (<xref ref-type="bibr" rid="B7">7</xref>), which systematically assessed monogenic causes of male infertility up to the year 2020. In contrast, our review expands the time frame to include all relevant studies published between January 2020 and September 2024, thereby providing a significantly updated evidence base. While we adopted a similar clinical validity scoring framework for consistency and comparability, we introduced several key methodological enhancements. For example, our review includes additional databases (e.g., Scopus and Ovid MEDLINE), We also re-evaluated previously reported gene&#x2013;disease relationships under updated evidence scoring, leading to reclassification of several GDRs based on newly published functional or clinical data.</p>
<sec id="s4_1">
<label>4.1</label>
<title>Clinical validity of gene&#x2013;disease relationships in male infertility</title>
<p>In our literature search, we employed a streamlined version of the comprehensive framework used by ClinGen to curate gene-disease relationships, resulting in evidence categorized similarly to ClinGen&#x2019;s method. This approach has been previously described and validated as reliable and reproducible, with outcomes that closely align with those derived from the ClinGen methodology. Consequently, it is well-suited for robust and efficient evaluation of genes in both research and diagnostic sequencing contexts (<xref ref-type="bibr" rid="B6">6</xref>). The results of this clinical validity assessment are dynamic and may evolve over time as the study progresses. Therefore, we anticipate that a significant number of genes currently classified as &#x201c;limited&#x201d; or &#x201c;No evidence&#x201d; may still play a crucial role in male infertility and should be valued in future genetic studies.</p>
<p>Importantly, Our clinical standardized assessment revealed that between January 1, 2020 and September 24, 2024, a total of 100 genes exhibited moderate-to-strong associations with male infertility or abnormal genitourinary developmental phenotypes, including 26 newly genes (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). The 2020 report identified 104 genes and phenotypes with moderate to strong supporting evidence. Compared to the prior systematic review by Houston et&#xa0;al. (<xref ref-type="bibr" rid="B7">7</xref>), which covered gene&#x2013;disease relationships from 1958 to 2020 and identified 104 genes with moderate to strong evidence, our study expands the landscape by analyzing 229 peer-reviewed articles published between 2020 and 2024. Through this, we identified 100 genes with at least moderate evidence, including 26 newly validated GDRs that had not been previously reported. Moreover, our study re-evaluated 106 previously assessed GDRs, leading to the reclassification of 50 genes whose evidence strength improved due to newly available functional or clinical data. This highlights how the increasing application of NGS and more standardized scoring systems have refined our understanding of the genetic architecture of male infertility. Unlike earlier reviews that primarily focused on isolated phenotypes such as NOA or globozoospermia, our study offers an expanded phenotype spectrum, encompassing complex syndromes such as PCD, DSD, and hormonal dysregulation syndromes. This broader scope reflects the ongoing shift from candidate-gene approaches toward comprehensive, phenotype-driven genomic assessments. Additionally, while previous reviews reported relatively few GDRs associated with sperm tail defects, our findings identified 15 genes confidently associated with MMAF, 5 of which are newly recognized (e.g., CFAP58, CFAP61, DNAH7, DNAH8, DNHD1). This further emphasizes our study&#x2019;s contribution to updating the molecular basis of distinct clinical subtypes.</p>
<p>Evidence from animal models was often strong, and genetic studies have clearly benefited from a large number of studies of well-characterized male infertility mouse models (<xref ref-type="bibr" rid="B10">10</xref>). However, caution is needed when drawing conclusions about gene function and inheritance patterns based solely on mouse models. Mice and humans do not have the same reproductive systems, and genes may have (slightly) different functions or transmit disease through different patterns of inheritance (<xref ref-type="bibr" rid="B11">11</xref>). Statistical evidence from large humans needs to be included in the assessment to supplement evidence from animal models with datasets (<xref ref-type="bibr" rid="B12">12</xref>).</p>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Recent advances in genetic research on male infertility (2020&#x2013;2024)</title>
<p>In most cases, male infertility is clinically diagnosed if semen parameters are reduced. Descriptive diagnoses are &#x201c;oligozoospermia&#x201d; (reduced sperm count), &#x201c;asthenozoospermia&#x201d;(reduced sperm motility),&#x201d;teratozoospermia&#x201d;(reduced percentage of sperm with normal morphology). Combinations are common; most frequently &#x201c;oligoasthenoteratozoospermia&#x201d; or &#x201c;OAT syndrome&#x201d; are found. The most severe clinical phenotype is &#x201c;azoospermia&#x201d;, i. e. no sperm are found in the ejaculate even after centrifugation. The frequency of these phenotypes varies significantly between primary care practice and specialized centers (<xref ref-type="bibr" rid="B13">13</xref>). Approximately 40% of males presenting with spermatogenic dysfunction demonstrate undetermined etiology despite comprehensive diagnostic evaluation (<xref ref-type="bibr" rid="B14">14</xref>). Emerging evidence suggests significant genetic contributions to idiopathic cases, driving systematic exploration through diverse genomic methodologies. Initial investigations during the 1990s primarily employed targeted resequencing of genes regulating endocrine pathways, cellular metabolism/proliferation, and meiotic processes. However, subsequent validation studies yielded inconsistent replication outcomes for proposed mutations/polymorphisms, raising methodological concerns given the estimated involvement of &gt;2,000 genes in spermatogenic regulation (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). The diagnostic rate of genetic tests for all types of isolated male infertility combined currently sits between 4% and 9.2% (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). The reason for the low diagnosis rate of these phenotypes is mainly due to the low application of NGS methods in the field of male infertility. WES and WGS are now routinely used for diagnostic follow-up in patients with other genetic disorders, and there are currently very large genetic cohort studies (<xref ref-type="bibr" rid="B19">19</xref>&#x2013;<xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>The integration of NGS into male infertility research has catalyzed transformative discoveries between 2020 and 2024, fundamentally expanding our understanding of its genetic architecture. This review&#x2014;have identified 85 novel genes associated with male infertility during this period, with 26 achieving moderate-to-definitive evidence for pathogenicity (<xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>). This substantial expansion of the genetic landscape, primarily driven by whole-exome/genome sequencing (adopted in 81.3% of included studies), underscores the accelerated pace of discovery enabled by high-throughput genomics.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Genes associated with male infertility with moderate or higher evidence, including newly identified genes (2020-2024).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" colspan="10" align="center">Isolated infertility</th>
</tr>
<tr>
<th valign="middle" align="left">Gene</th>
<th valign="middle" align="left">Location</th>
<th valign="middle" align="left">Disorder</th>
<th valign="middle" align="left">OMIM ID</th>
<th valign="middle" align="left">Inheritance</th>
<th valign="middle" align="left">Score in 2020</th>
<th valign="middle" align="left">Conclusion in 2020</th>
<th valign="middle" align="left">Score in 2024</th>
<th valign="middle" align="left">Conclusion in 2024</th>
<th valign="middle" align="left">Change 2020 to 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">ACTL7A</td>
<td valign="middle" align="left">9q31.3</td>
<td valign="middle" align="left">Fertilization failure</td>
<td valign="middle" align="left">620499</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">Unable to classify</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">ACTL9*</td>
<td valign="middle" align="left">19p13.2</td>
<td valign="middle" align="left">Fertilization failure</td>
<td valign="middle" align="left">619258</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">ADGRG2</td>
<td valign="middle" align="left">Xp22.13</td>
<td valign="middle" align="left">Congenital bilateral absence of the vas deferens</td>
<td valign="middle" align="left">300985</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">ARMC2</td>
<td valign="middle" align="left">6q21</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">618433</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">ATG4D*</td>
<td valign="middle" align="left">19p13.2</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">611340</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">AURKC</td>
<td valign="middle" align="left">19q13.43</td>
<td valign="middle" align="left">Macrozoospermia</td>
<td valign="middle" align="left">243060</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">BCORL1</td>
<td valign="middle" align="left">Xq26.1</td>
<td valign="middle" align="left">Oligoasthenoteratozoospermia</td>
<td valign="middle" align="left">300688</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">CCDC34*</td>
<td valign="middle" align="left">11p14.1</td>
<td valign="middle" align="left">Oligoasthenoteratozoospermia</td>
<td valign="middle" align="left">620084</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">CFAP43</td>
<td valign="middle" align="left">10q25.1</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">617592</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">CFAP44</td>
<td valign="middle" align="left">3q13.2</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">617593</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">CFAP58*</td>
<td valign="middle" align="left">10q25.1</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">619144</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">CFAP61*</td>
<td valign="middle" align="left">20p11.23</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">620409</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">CFAP69</td>
<td valign="middle" align="left">7q21.13</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">617959</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">CFTR</td>
<td valign="middle" align="left">7q31.2</td>
<td valign="middle" align="left">Congenital bilateral absence of the vas deferens</td>
<td valign="middle" align="left">277180</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">DMC1</td>
<td valign="middle" align="left">22q13.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">602721</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">DMRT1</td>
<td valign="middle" align="left">9p24.3</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">NA</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH1</td>
<td valign="middle" align="left">3p21.1</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">617576</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH10*</td>
<td valign="middle" align="left">12q24.31</td>
<td valign="middle" align="left">asthenoteratozoospermia</td>
<td valign="middle" align="left">619515</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH17</td>
<td valign="middle" align="left">17q25.3</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">618643</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH6</td>
<td valign="middle" align="left">2p11.2</td>
<td valign="middle" align="left">asthenoteratozoospermia</td>
<td valign="middle" align="left">603336</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH7*</td>
<td valign="middle" align="left">2q32.3</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">620356</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH8*</td>
<td valign="middle" align="left">6p21.2</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">619095</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">DNHD1*</td>
<td valign="middle" align="left">11p15.4</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">619712</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">DPY19L2</td>
<td valign="middle" align="left">12q14.2</td>
<td valign="middle" align="left">Globozoospermia</td>
<td valign="middle" align="left">613958</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">DRC3*</td>
<td valign="middle" align="left">17p11.2</td>
<td valign="middle" align="left">asthenozoospermia</td>
<td valign="middle" align="left">NA</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">FANCA</td>
<td valign="middle" align="left">16q24.3</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">227650</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">FANCM</td>
<td valign="middle" align="left">14q21.2</td>
<td valign="middle" align="left">azoospermia</td>
<td valign="middle" align="left">618086</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">FSIP2</td>
<td valign="middle" align="left">2q32.1</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">618153</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">GCNA*</td>
<td valign="middle" align="left">Xq13.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">301077</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">IFT140*</td>
<td valign="middle" align="left">16p13.3</td>
<td valign="middle" align="left">Oligoasthenoteratozoospermia</td>
<td valign="middle" align="left">617781</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">IGSF1*</td>
<td valign="middle" align="left">Xq26.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">300888</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">KASH5</td>
<td valign="middle" align="left">19q13.33</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">620547</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">LRRC23*</td>
<td valign="middle" align="left">12p13.31</td>
<td valign="middle" align="left">asthenozoospermia</td>
<td valign="middle" align="left">620848</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">M1AP</td>
<td valign="middle" align="left">2p13.1</td>
<td valign="middle" align="left">Oligozoospermia</td>
<td valign="middle" align="left">619108</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">MEIOB</td>
<td valign="middle" align="left">16p13.3</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">617706</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">MSH4</td>
<td valign="middle" align="left">1p31.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">108420</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">&#x2264; 2</td>
<td valign="middle" align="left">No evidence</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">MSH5*</td>
<td valign="middle" align="left">6p21.33</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">619937</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">PLCZ1</td>
<td valign="middle" align="left">12p12.3</td>
<td valign="middle" align="left">Fertilization failure</td>
<td valign="middle" align="left">617214</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">PLK4</td>
<td valign="middle" align="left">4q28.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">NA</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">PMFBP1</td>
<td valign="middle" align="left">16q22.2</td>
<td valign="middle" align="left">Acephalic spermatozoa</td>
<td valign="middle" align="left">618112</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">PNLDC1*</td>
<td valign="middle" align="left">6q25.3</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">619528</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">QRICH2</td>
<td valign="middle" align="left">17q25.1</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">618341</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">RHOXF1</td>
<td valign="middle" align="left">Xq24</td>
<td valign="middle" align="left">Oligozoospermia</td>
<td valign="middle" align="left">NA</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">&#x2264; 2</td>
<td valign="middle" align="left">No evidence</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">RXFP2</td>
<td valign="middle" align="left">13q13.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">NA</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">SEPTIN12</td>
<td valign="middle" align="left">16p13.3</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">614822</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">SHOC1*</td>
<td valign="middle" align="left">9q31.3</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">619949</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">SLC26A8*</td>
<td valign="middle" align="left">6p21.31</td>
<td valign="middle" align="left">asthenoteratozoospermia</td>
<td valign="middle" align="left">606766</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">SLC9A3</td>
<td valign="middle" align="left">5p15.33</td>
<td valign="middle" align="left">Congenital bilateral absence of the vas deferens</td>
<td valign="middle" align="left">182307</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">SPATA22*</td>
<td valign="middle" align="left">17p13.2</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">621001</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">SPEF2</td>
<td valign="middle" align="left">5p13.2</td>
<td valign="middle" align="left">Multiple morphological abnormalities of the sperm flagella</td>
<td valign="middle" align="left">618751</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">STAG3</td>
<td valign="middle" align="left">7q22.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">619672</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">SUN5</td>
<td valign="middle" align="left">20q11.21</td>
<td valign="middle" align="left">Acephalic spermatozoa</td>
<td valign="middle" align="left">617187</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">SYCE1</td>
<td valign="middle" align="left">10q26.3</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">616950</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">SYCP2</td>
<td valign="middle" align="left">20q13.33</td>
<td valign="middle" align="left">oligoasthenozoospermia</td>
<td valign="middle" align="left">258150</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">TDRD9</td>
<td valign="middle" align="left">14q32.33</td>
<td valign="middle" align="left">Oligozoospermia</td>
<td valign="middle" align="left">618110</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">TERB1*</td>
<td valign="middle" align="left">16q22.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">619646</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">TEX11</td>
<td valign="middle" align="left">Xq13.1</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">309120</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">TEX15</td>
<td valign="middle" align="left">8p12</td>
<td valign="middle" align="left">Fertilization failure</td>
<td valign="middle" align="left">617960</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">TKTL1*</td>
<td valign="middle" align="left">Xq28</td>
<td valign="middle" align="left">Non-obstructive azoospermia</td>
<td valign="middle" align="left">300044</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">TSGA10</td>
<td valign="middle" align="left">2q11.2</td>
<td valign="middle" align="left">Acephalic spermatozoa</td>
<td valign="middle" align="left">617961</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">USP26</td>
<td valign="middle" align="left">Xq26.2</td>
<td valign="middle" align="left">Oligozoospermia</td>
<td valign="middle" align="left">301101</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">ZMYND15</td>
<td valign="middle" align="left">17p13.2</td>
<td valign="middle" align="left">Oligoasthenoteratozoospermia</td>
<td valign="middle" align="left">615842</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<th valign="middle" colspan="10" align="center">Syndromic infertility</th>
</tr>
<tr>
<td valign="middle" align="left">ADCY10</td>
<td valign="middle" align="left">1q24.2</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">143870</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">ARL2BP</td>
<td valign="middle" align="left">16q13</td>
<td valign="middle" align="left">Asthenozoospermia and Retinitis Pigmentosa</td>
<td valign="middle" align="left">615434</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">ARMC4</td>
<td valign="middle" align="left">10p12.1</td>
<td valign="middle" align="left">Deafness-infertility syndrome</td>
<td valign="middle" align="left">615451</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">CCDC103</td>
<td valign="middle" align="left">17q21.31</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">614679</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">CCDC151*</td>
<td valign="middle" align="left">19p13.2</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">616037</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">CCDC39</td>
<td valign="middle" align="left">3q26.33</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">613807</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">CCDC40</td>
<td valign="middle" align="left">17q25.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">613808</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">CDC14A</td>
<td valign="middle" align="left">1p21.2</td>
<td valign="middle" align="left">Hearing impairment infertility male syndrome</td>
<td valign="middle" align="left">608653</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">DNAAF1*</td>
<td valign="middle" align="left">16q24.1</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">613193</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">DNAAF2</td>
<td valign="middle" align="left">14q21.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">612518</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">DNAAF4</td>
<td valign="middle" align="left">15q21.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">615482</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">DNAAF6</td>
<td valign="middle" align="left">Xq22.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">300991</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH11*</td>
<td valign="middle" align="left">7p15.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">611884</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">DNAH5</td>
<td valign="middle" align="left">5p15.2</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">608644</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">DNAI1</td>
<td valign="middle" align="left">9p13.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">244400</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">HYDIN</td>
<td valign="middle" align="left">16q22.2</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">608647</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">LRRC6</td>
<td valign="middle" align="left">8q24.22</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">614935</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">MNS1</td>
<td valign="middle" align="left">15q21.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">618948</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">RSPH3</td>
<td valign="middle" align="left">6q25.3</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">616481</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">RSPH4A*</td>
<td valign="middle" align="left">6q22.1</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">612649</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<td valign="middle" align="left">TTC12*</td>
<td valign="middle" align="left">11q23.2</td>
<td valign="middle" align="left">Primary ciliary dyskinesia</td>
<td valign="middle" align="left">618801</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">N/A</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">New gene</td>
</tr>
<tr>
<th valign="middle" colspan="10" align="center">Endocrine disorder/Reproductive system syndrome</th>
</tr>
<tr>
<td valign="middle" align="left">AMH</td>
<td valign="middle" align="left">19p13.3</td>
<td valign="middle" align="left">Persistent M&#xfc;llerian duct syndrome</td>
<td valign="middle" align="left">261550</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">AMHR2</td>
<td valign="middle" align="left">12q13.13</td>
<td valign="middle" align="left">Persistent M&#xfc;llerian duct syndrome</td>
<td valign="middle" align="left">261550</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">ANOS1</td>
<td valign="middle" align="left">Xp22.31</td>
<td valign="middle" align="left">Kallmann syndrome</td>
<td valign="middle" align="left">308700</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">Xq12</td>
<td valign="middle" align="left">46,XY Disorders of sexual development</td>
<td valign="middle" align="left">312300</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">CHD7</td>
<td valign="middle" align="left">8q12.2</td>
<td valign="middle" align="left">Hypogonadotropic hypogonadism</td>
<td valign="middle" align="left">612370</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">CYP19A1</td>
<td valign="middle" align="left">15q21.2</td>
<td valign="middle" align="left">Aromatase deficiency</td>
<td valign="middle" align="left">613546</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">DHH</td>
<td valign="middle" align="left">12q13.12</td>
<td valign="middle" align="left">46,XY Disorders of sexual development</td>
<td valign="middle" align="left">233420</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Moderate</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">FGFR1</td>
<td valign="middle" align="left">8p11.23</td>
<td valign="middle" align="left">Kallmann syndrome</td>
<td valign="middle" align="left">147950</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">ANOS1</td>
<td valign="middle" align="left">Xp22.31</td>
<td valign="middle" align="left">Kallmann syndrome</td>
<td valign="middle" align="left">308700</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">KISS1R</td>
<td valign="middle" align="left">19p13.3</td>
<td valign="middle" align="left">Hypogonadotropic hypogonadism</td>
<td valign="middle" align="left">614837</td>
<td valign="middle" align="left">AR</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">MAP3K1</td>
<td valign="middle" align="left">5q11.2</td>
<td valign="middle" align="left">46,XY Disorders of sexual development</td>
<td valign="middle" align="left">613762</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Limited</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">Strong</td>
<td valign="middle" align="left">Classification increased</td>
</tr>
<tr>
<td valign="middle" align="left">NR0B1</td>
<td valign="middle" align="left">Xp21.2</td>
<td valign="middle" align="left">46,XY Disorders of sexual development</td>
<td valign="middle" align="left">300018</td>
<td valign="middle" align="left">XL</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">NR5A1</td>
<td valign="middle" align="left">9q33.3</td>
<td valign="middle" align="left">46,XY Disorders of sexual development</td>
<td valign="middle" align="left">612965</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">PROKR2</td>
<td valign="middle" align="left">20p12.3</td>
<td valign="middle" align="left">Kallmann syndrome</td>
<td valign="middle" align="left">244200</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">SEMA3A</td>
<td valign="middle" align="left">7q21.11</td>
<td valign="middle" align="left">hypogonadotropic hypogonadism</td>
<td valign="middle" align="left">614897</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">SOX10</td>
<td valign="middle" align="left">22q13.1</td>
<td valign="middle" align="left">Hypogonadotropic hypogonadism</td>
<td valign="middle" align="left">613266</td>
<td valign="middle" align="left">AD</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
<tr>
<td valign="middle" align="left">SRY</td>
<td valign="middle" align="left">Yp11.2</td>
<td valign="middle" align="left">46,XX Disorders of sexual development</td>
<td valign="middle" align="left">400045</td>
<td valign="middle" align="left">YL</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">Definitive</td>
<td valign="middle" align="left">No change</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AR, autosomal recessive; AD, autosomal dominant; XL, X-linked; YL, Y-linked.</p>
</fn>
<fn>
<p>
<bold>*</bold>New genes. New genes were identified through our systematic review of literature published between January 1, 2020, and September 24, 2024. These genes were not reported in the prior comprehensive review by Houston et&#xa0;al. (2021) (<xref ref-type="bibr" rid="B7">7</xref>), which covered publications up to 2020. In our study, a total of 27 new genes were classified as having moderate or higher evidence, among which 22 were associated with isolated infertility and 5 with syndromic infertility.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Critical breakthroughs have emerged in the genetic dissection of sperm tail defects, particularly regarding MMAF. Sperm tail defects mainly manifest in the form of MMAF, characterized by artifacts in the axonemal microtubules, mitochondrial arrangement, head and neck connection, fagellar sheath abnormalities, and short, abnormally shaped, bent, or coiled fagellum (<xref ref-type="bibr" rid="B22">22</xref>). In our review, research during this period established 15 genes (<italic>ARMC2, CFAP43, CFAP44, CFAP58, CFAP61, CFAP69, DNAH1, DNAH17, DNAH7, DNAH8, DNHD1, FSIP2, QRICH2, SEPTIN12, SPEF2</italic>) with at least moderate evidence for causality. Significantly, five of these (<italic>CFAP58, CFAP61, DNAH7, DNAH8, DNHD1</italic>) represent newly validated associations since 2020 (<xref ref-type="table" rid="T2">
<bold>Tables&#xa0;2</bold>
</xref>, <xref ref-type="table" rid="T3">
<bold>3</bold>
</xref>). NGS-based approaches now achieve diagnostic yields approaching 50% in MMAF cohorts, transforming this severe phenotype from idiopathic to genetically characterized.</p>
<p>PCD, alternatively termed immotile cilia syndrome, represents an autosomal recessive disorder with multisystem involvement, manifesting as chronic sino-pulmonary infections; visceral situs anomalies; and asthenozoospermia secondary to structural/functional ciliary and flagellar anomalies (<xref ref-type="bibr" rid="B23">23</xref>). Notably, diagnostic challenges associated with phenotypic variability and technical limitations in ciliary ultrastructural analysis likely contribute to significant underrecognition of this condition (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). While spermatozoa in the majority of PCD cases demonstrate preserved morphological integrity under conventional light microscopy, pathognomonic ultrastructural anomalies discernible exclusively via transmission electron microscopy persist - including dynein arm deficiencies, microtubular disarrangements, and radial spoke absences (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Parallel advances refined the genetic basis of syndromic infertility, notably PCD and its mechanistic links to sperm immotility. Our synthesis confirms 18 genes with robust evidence for PCD-associated male infertility (<italic>ADCY10, ARL2BP, CCDC151, CCDC39, CCDC40, CDC14A, DNAAF1, DNAAF2, DNAAF4, DNAAF6, DNAH11, DNAH5, DNAI1, HYDIN, LRRC6, MNS1, RSPH3, RSPH4A, TTC12</italic>), highlighting shared pathways between somatic ciliary function and sperm flagellar integrity. These studies concurrently emphasized diagnostic challenges posed by phenotypic heterogeneity and the indispensable role of transmission electron microscopy in detecting ultrastructural defects invisible to conventional semen analysis.</p>
<p>Beyond gene discovery, this period yielded deeper mechanistic insights. Investigations into genes such as <italic>SEPTIN12</italic> revealed mutations causing combined sperm head-tail malformations, linking cytoskeletal regulation to pleiotropic defects (<xref ref-type="bibr" rid="B28">28</xref>). Robust validation efforts using animals models and expanded clinical cohorts characterized this era. These led to the reclassification of 50 previously reported GDRs, strengthening their evidence levels based on new functional data (e.g., protein studies, animal phenocopy) or larger patient datasets. A paradigm shift toward phenotype-driven genomic analyses became firmly established. The field progressively moved beyond candidate-gene approaches to embrace comprehensive WES/WGS strategies. This shift proves essential for identifying variants in genes without prior infertility associations and for detecting potential oligogenic contributions&#x2014;though the latter remains a key frontier for future investigation.</p>
<p>Collectively, these advances underscore the dynamic nature of male infertility genetics. The identification of 82 genes with limited evidence in this review highlights substantial discovery potential. While rising diagnostic yields&#x2014;particularly for severe phenotypes like MMAF and NOA&#x2014;validate NGS utility, they also emphasize the urgency of developing scalable functional validation pipelines to confirm pathogenicity and decipher molecular mechanisms.</p>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>Recommendations for genetic testing in male infertility</title>
<p>Genetic testing has become increasingly important in the management and counselling of infertile males. The two main purposes of genetic testing in infertility are: to determine genetic conditions that may be inherited by offspring and to assess conditions that may affect the success of assisted reproductive technologies (<xref ref-type="bibr" rid="B29">29</xref>). Current diagnostic guidelines endorse three principal genetic evaluations as standard practice in male infertility assessment: KA for chromosomal architecture; Y-chromosomal microdeletion screening for AZF region integrity; and CFTR gene mutational analysis (<xref ref-type="bibr" rid="B30">30</xref>).</p>
<p>KA is a cytogenetic method using a microscope to observe chromosomes during cell division and detect abnormalities like number changes (e.g., trisomy, deletion) or structural variations (e.g., inversion, translocation) (<xref ref-type="bibr" rid="B21">21</xref>). It is the primary genetic test for infertile men, finding chromosomal issues in about 15% of non-obstructive azoospermia and 4% of severe oligozoospermia cases (&lt;10&#xd7;10<sup>6</sup>/mL sperm) (<xref ref-type="bibr" rid="B31">31</xref>). EAU guidelines also recommend karyotyping for couples with recurrent miscarriage, malformation, cognitive impairment, or family infertility history, regardless of sperm count (<xref ref-type="bibr" rid="B4">4</xref>). The main abnormality in nonobstructive azoospermia is Klinefelter syndrome and variants (47,XXY; 46,XY/47,XXY mosaics), while structural autosomal issues (translocations, inversions) are more common in oligozoospermic men (<xref ref-type="bibr" rid="B4">4</xref>). The Y chromosome has short (Yp) and long (Yq) arms separated by a centromere and is about 60 megabases long. Notably, 95% of its DNA is the male-specific region (MSY), a key area controlling male development and sperm production (<xref ref-type="bibr" rid="B32">32</xref>). Clinically important Y chromosome microdeletions (AZFa, AZFb, AZFc) are well-studied due to their many spermatogenesis genes (<xref ref-type="bibr" rid="B33">33</xref>). These microdeletions don&#x2019;t occur in men with normal sperm counts and are rare with counts &gt;5&#xd7;10<sup>6</sup>/mL (<xref ref-type="bibr" rid="B34">34</xref>). Current EAU guidelines thus adjust testing by semen levels: microdeletion screening is optional for low sperm counts (&lt;5&#xd7;10<sup>6</sup>/mL) but required for no sperm or very low counts (&#x2264;1&#xd7;10<sup>6</sup>/mL) (<xref ref-type="bibr" rid="B35">35</xref>). The CFTR gene on chromosome 7 spans about 250 kb and encodes a cAMP-regulated chloride channel mainly in epithelial membranes. Over 2,000 disease-causing variants exist, with effects from unnoticeable to life-threatening organ failure (<xref ref-type="bibr" rid="B36">36</xref>). Over 1,500 distinct variants are known, some strongly linked to congenital bilateral absence of the vas deferens (CBAVD) (<xref ref-type="bibr" rid="B37">37</xref>). Careful diagnosis is vital for CBAVD as it&#x2019;s often missed. All men without sperm need thorough exams to check for CBAVD, especially those with low semen volume (&lt;1.0 mL) and acidic pH (&lt;7.0). For infertile men with CFTR variants, protocols require CFTR carrier screening and genetic counseling for female partners, since children have 50% cystic fibrosis risk if the mother is a carrier (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>As a revolutionary genomic tool, NGS provides high-throughput analysis of substantial genomic segments with unprecedented precision and speed, while achieving significant cost-efficiency compared to traditional sequencing methodologies. Currently, NGS has three applications: targeted sequencing (TS), WES, and WGS (<xref ref-type="bibr" rid="B38">38</xref>). Recent advancements in genomics have provided profound insights into the genetic underpinnings of male infertility, leveraging WES and WGS to identify novel genes and variants affecting sperm development, structure, and function (<xref ref-type="bibr" rid="B39">39</xref>). WES has been instrumental in detecting pathogenic variants across a spectrum of conditions related to male reproductive failure. Alternatively, WGS offers a broader genomic perspective, enabling the identification of structural variants (SVs) and complex genetic rearrangements that WES might miss. Among the 229 literatures included, 197 (85.65%) used NGS tests, among which WES tests were the most widely used (87.82%). Because the genetic etiology of male infertility is very complex, involving many genes, and most of the mutations have not been reported, it is recommended to use NGS to detect multiple related genes at the same time.</p>
<p>The identification of 100 genes with moderate to definitive evidence provides a robust foundation for updating diagnostic gene panels for male infertility. Clinically, incorporating these genes into routine diagnostic workflows&#x2014;especially in tertiary infertility centers&#x2014;may increase the diagnostic yield for idiopathic cases, particularly those presenting with severe phenotypes like NOA or MMAF. For instance, genes such as CFAP43, CFAP44, and DNAH1, which are strongly associated with MMAF, can inform the decision for sperm retrieval attempts (e.g., testicular sperm extraction) and reduce the number of unnecessary surgical interventions. Similarly, identification of CFTR or ADGRG2 mutations in patients with CBAVD has direct implications for assisted reproductive technology (ART), such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic testing (PGT). Furthermore, pathogenic variants in syndromic genes such as ANOS1, NR5A1, or AMH necessitate careful genetic counseling regarding inheritance risks and potential extra-gonadal manifestations. These considerations are essential when counseling couples regarding their reproductive options, including donor sperm, PGT, or prenatal diagnosis.</p>
<p>Taken together, the integration of these findings into clinical practice may not only enhance the diagnostic rate but also guide personalized reproductive planning, improve ART outcomes, and ensure more informed genetic counseling for affected individuals and their partners.</p>
</sec>
<sec id="s4_4">
<label>4.4</label>
<title>State-of-the-art perspectives: emerging trends and technologies</title>
<p>The advent of long-read sequencing (LRS) represents a pivotal technological breakthrough in genetic analysis, particularly in the realm of male reproductive biology. This disruptive technology has fundamentally transformed our ability to detect and characterize SVs and haplotype variants with unprecedented precision and resolution. Unlike NGS, which relies on short reads that often fail to span complex genomic regions, LRS can sequence DNA fragments ranging from kilobases to megabases in length. This capability allows for the comprehensive detection of SVs, including those in repetitive or difficult-to-sequence areas of the genome that NGS typically misses (<xref ref-type="bibr" rid="B40">40</xref>). Moreover, LRS can facilitate the detection of SVs that play critical roles in spermatogenesis and male fertility. For instance, the comprehensive sequencing of the Y chromosome using LRS has added over 30 million base pairs that were previously missing, including complete structures of gene families crucial for spermatogenesis like TSPY, DAZ, and RBMY (<xref ref-type="bibr" rid="B41">41</xref>). This advancement not only improves the diagnostic accuracy for Y-chromosome-related infertility issues but also enables the identification of subtle genetic variations that contribute to male infertility. Overall, LRS is revolutionizing the field of genetic analysis by providing a more thorough and accurate understanding of genomic variations and their impacts on clinically relevant conditions (<xref ref-type="bibr" rid="B42">42</xref>). Its ability to resolve complex genomic regions, phase variants with unprecedented accuracy, and detect a wide array of SVs, is making it an indispensable asset in the quest to unravel the genetic underpinnings of male infertility.</p>
<p>Parallel innovations in functional validation are overcoming the translatability limitations of traditional animal models. While animal models have been pivotal for functional validation, advances in human-derived <italic>in vitro</italic> systems&#x2014;such as CRISPR-edited germ cell lines (<xref ref-type="bibr" rid="B43">43</xref>), organoids (<xref ref-type="bibr" rid="B44">44</xref>), and induced pluripotent stem cell (iPSC)-derived gametes (<xref ref-type="bibr" rid="B45">45</xref>)&#x2014;offer human-specific mechanistic insights. These models bridge the translational gap, enabling rapid functional validation of candidate variants and assessment of therapeutic interventions.</p>
</sec>
<sec id="s4_5">
<label>4.5</label>
<title>Future challenges and opportunities</title>
<p>As emphasized in this review, the number of identified GDR and genes associated with male infertility has increased dramatically over the past few decades. Therefore, we anticipate that an increasing number of new genes will be recognized, and a significant portion of gdr that are currently rated as below moderate evidence will gain importance in their role in male infertility. Our work will greatly facilitate basic research into male infertility genes, or how they affect fertility and how to mitigate their effects. Despite significant advances in uncovering monogenic causes of male infertility, several key challenges remain unresolved, while promising opportunities are emerging in parallel. Addressing these gaps will be essential to translating genetic insights into clinical practice.</p>
<p>Moving forward, one key research priority will be addressing the persistent &#x201c;missing heritability&#x201d; in idiopathic cases, which may be driven by oligogenic or polygenic contributions, epigenetic modifications, or complex gene&#x2013;environment interactions not captured by current monogenic frameworks. Integrating polygenic risk models, epigenomic profiling, and environmental exposure data into future study designs may help uncover novel etiological pathways.</p>
<p>Another promising direction lies in expanding research beyond severe phenotypes such as NOA and MMAF, to include milder and under-recognized forms of male infertility. This will require recruitment of diverse and underrepresented populations to ensure that genetic discoveries are globally relevant and to uncover population-specific variants.</p>
<p>Functional validation remains a bottleneck for translating genetic associations into clinical practice. While animal models have been invaluable, their limitations in replicating human reproductive biology highlight the need for human-based systems, such as CRISPR-edited germ cell lines, induced pluripotent stem cell-derived gametogenesis models, and advanced organoid platforms. These approaches, combined with high-resolution imaging and single-cell omics, may provide more accurate insights into gene function and pathogenic mechanisms.</p>
<p>From a translational perspective, building comprehensive, curated, and regularly updated gene&#x2013;disease databases will be critical for harmonizing clinical genetic testing and variant interpretation. International collaborations could facilitate standardized guidelines for genetic testing in male infertility, improving diagnostic yield and enabling personalized reproductive counseling. The incorporation of multi-omics into diagnostic workflows, particularly in tertiary infertility centers, may further refine patient stratification and treatment planning.</p>
<p>Finally, as genetic testing becomes increasingly integrated into infertility care, ethical considerations surrounding data privacy, incidental findings, and reproductive decision-making must be proactively addressed. Establishing robust frameworks for genetic counseling and informed consent will be essential to ensure that advances in genomic medicine translate into patient-centered benefits.</p>
<p>In summary, the next decade will likely see the convergence of large-scale, multi-omic discovery efforts, advanced functional genomics, and clinically embedded genetic testing, moving the field closer to comprehensive, personalized, and equitable care for men with infertility.</p>
</sec>
<sec id="s4_6">
<label>4.6</label>
<title>Strengths and limitations</title>
<p>This study allowed us to assign robust and reproducible clinical validity scores to 191 GDRs. However, our work is limited to monogenic causes of male infertility and does not take into account associated genetic risk factor(s) or oligogenic/polygenic causes of male infertility. And systematic reviews inherently suffer from publication time lags, potentially missing significant studies released after September 2024. Given the field&#x2019;s dynamic nature, these validity classifications represent a temporal snapshot requiring continual reassessment.</p>
<p>Our study was limited to literature databases and did not include specialized genetic databases such as ClinVar or OMIM. While these resources contain valuable information about gene-disease relationships and variant classifications, we focused our systematic review on peer-reviewed publications that provided both genetic and detailed phenotypic information. Future updates to this assessment would benefit from incorporating these specialized genetic databases to provide even more comprehensive coverage of established GDRs in male infertility.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p>In this updated clinical validity assessment, we evaluated a total of 191 genes with reported monogenic association to male infertility and identified 100 gene&#x2013;disease relationships with at least moderate evidence for a role in male infertility. Of these 191 genes, 85 genes were not reported in previous studies and 26 gene&#x2013;disease relationships with at least moderate evidence. Our results and our objective methodology and recommendations may contribute to improving genetic testing in the research or diagnosis of male infertility.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>QZ: Writing &#x2013; original draft, Formal analysis, Resources, Writing &#x2013; review &amp; editing, Software, Visualization, Methodology, Supervision, Conceptualization, Investigation, Validation, Data curation. HP: Funding acquisition, Visualization, Project administration, Validation, Resources, Supervision, Data curation, Methodology, Investigation, Writing &#x2013; original draft, Conceptualization. JC: Supervision, Writing &#x2013; original draft, Software, Investigation, Data curation, Methodology, Validation. HZ: Software, Investigation, Writing &#x2013; original draft, Validation, Methodology, Supervision, Data curation. YM: Validation, Funding acquisition, Conceptualization, Resources, Writing &#x2013; review &amp;&#xa0;editing, Project administration, Supervision, Visualization. HJ:&#xa0;Resources, Writing &#x2013; review &amp; editing, Funding acquisition, Visualization, Project administration, Conceptualization, Supervision, Validation.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research and/or publication of this article. This work is funded in part by the research grant from the Application Research Project of Science and Technology Research and Development Plan Joint Fund of Henan Province in China (No. 232103810049) and the Key Project of Science and Technology Research and Development Joint Fund of Henan Province in China (No. 225200810054).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="correction-statement">
<title>Correction note</title>
<p>A correction has been made to this article. Details can be found at: <ext-link  xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.3389/fendo.2025.1695432">10.3389/fendo.2025.1695432</ext-link>.</p>
</sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fendo.2025.1643543/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fendo.2025.1643543/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SF1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document">
<label>Supplementary Data Sheet 1</label>
<caption>
<p>(.\SR\&#x8865;&#x5145;&#x8868;\Supplementary Table S1.docx).</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Table2.xlsx" id="SF2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet">
<label>Supplementary Data Sheet 2</label>
<caption>
<p>(.\SR\&#x8865;&#x5145;&#x8868;\Supplementary Table S2.xlsx).</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Table3.xlsx" id="SF3" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet">
<label>Supplementary Data Sheet 3</label>
<caption>
<p>(.\SR\&#x8865;&#x5145;&#x8868;\Supplementary Table S3.xlsx).</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>WHO</collab>
</person-group>. <article-title>1 in 6 people globally affected by infertility</article-title>. <publisher-name>WHO</publisher-name>. (<year>2023</year>). Available online at: <uri xlink:href="https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility/">https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility/</uri> (Accessed November 21, 2024).</citation></ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agarwal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mulgund</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hamada</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chyatte</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>A unique view on male infertility around the globe</article-title>. <source>Reprod Biol Endocrinol</source>. (<year>2015</year>) <volume>13</volume>:<fpage>37</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12958-015-0032-1</pub-id>, PMID: <pub-id pub-id-type="pmid">25928197</pub-id></citation></ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tournaye</surname> <given-names>H</given-names>
</name>
<name>
<surname>Krausz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Oates</surname> <given-names>RD</given-names>
</name>
</person-group>. <article-title>Novel concepts in the aetiology of male reproductive impairment</article-title>. <source>Lancet Diabetes Endocrinol</source>. (<year>2017</year>) <volume>5</volume>:<page-range>544&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2213-8587(16)30040-7</pub-id>, PMID: <pub-id pub-id-type="pmid">27395771</pub-id></citation></ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krausz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Riera-Escamilla</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Genetics of male infertility</article-title>. <source>Nat Rev Urol</source>. (<year>2018</year>) <volume>15</volume>:<page-range>369&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41585-018-0003-3</pub-id>, PMID: <pub-id pub-id-type="pmid">29622783</pub-id></citation></ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strande</surname> <given-names>NT</given-names>
</name>
<name>
<surname>Riggs</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Buchanan</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Ceyhan-Birsoy</surname> <given-names>O</given-names>
</name>
<name>
<surname>DiStefano</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dwight</surname> <given-names>SS</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource</article-title>. <source>Am J Hum Genet</source>. (<year>2017</year>) <volume>100</volume>:<fpage>895</fpage>&#x2013;<lpage>906</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.04.015</pub-id>, PMID: <pub-id pub-id-type="pmid">28552198</pub-id></citation></ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname> <given-names>ED</given-names>
</name>
<name>
<surname>Radtke</surname> <given-names>K</given-names>
</name>
<name>
<surname>Rossi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shinde</surname> <given-names>DN</given-names>
</name>
<name>
<surname>Darabi</surname> <given-names>S</given-names>
</name>
<name>
<surname>El-Khechen</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Classification of genes: standardized clinical validity assessment of gene-disease associations aids diagnostic exome analysis and reclassifications</article-title>. <source>Hum Mutat</source>. (<year>2017</year>) <volume>38</volume>:<page-range>600&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/humu.23183</pub-id>, PMID: <pub-id pub-id-type="pmid">28106320</pub-id></citation></ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houston</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Riera-Escamilla</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wyrwoll</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Salas-Huetos</surname> <given-names>A</given-names>
</name>
<name>
<surname>Xavier</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Nagirnaja</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>A systematic review of the validated monogenic causes of human male infertility: 2020 update and a discussion of emerging gene-disease relationships</article-title>. <source>Hum Reprod Update</source>. (<year>2021</year>) <volume>28</volume>:<fpage>15</fpage>&#x2013;<lpage>29</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/humupd/dmab030</pub-id>, PMID: <pub-id pub-id-type="pmid">34498060</pub-id></citation></ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Page</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>McKenzie</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Bossuyt</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Boutron</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hoffmann</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Mulrow</surname> <given-names>CD</given-names>
</name>
<etal/>
</person-group>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>372</volume>:<elocation-id>n71</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>, PMID: <pub-id pub-id-type="pmid">33782057</pub-id></citation></ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tour&#xe9;</surname> <given-names>A</given-names>
</name>
<name>
<surname>Martinez</surname> <given-names>G</given-names>
</name>
<name>
<surname>Kherraf</surname> <given-names>ZE</given-names>
</name>
<name>
<surname>Cazin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Beurois</surname> <given-names>J</given-names>
</name>
<name>
<surname>Arnoult</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The genetic architecture of morphological abnormalities of the sperm tail</article-title>. <source>Hum Genet</source>. (<year>2021</year>) <volume>140</volume>:<fpage>21</fpage>&#x2013;<lpage>42</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00439-020-02113-x</pub-id>, PMID: <pub-id pub-id-type="pmid">31950240</pub-id></citation></ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kherraf</surname> <given-names>ZE</given-names>
</name>
<name>
<surname>Conne</surname> <given-names>B</given-names>
</name>
<name>
<surname>Amiri-Yekta</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kent</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Coutton</surname> <given-names>C</given-names>
</name>
<name>
<surname>Escoffier</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Creation of knock out and knock in mice by CRISPR/Cas9 to validate candidate genes for human male infertility, interest, difficulties and feasibility</article-title>. <source>Mol Cell Endocrinol</source>. (<year>2018</year>) <volume>468</volume>:<fpage>70</fpage>&#x2013;<lpage>80</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mce.2018.03.002</pub-id>, PMID: <pub-id pub-id-type="pmid">29522859</pub-id></citation></ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieschke</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Currie</surname> <given-names>PD</given-names>
</name>
</person-group>. <article-title>Animal models of human disease: zebrafish swim into view</article-title>. <source>Nat Rev Genet</source>. (<year>2007</year>) <volume>8</volume>:<page-range>353&#x2013;67</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrg2091</pub-id>, PMID: <pub-id pub-id-type="pmid">17440532</pub-id></citation></ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lek</surname> <given-names>M</given-names>
</name>
<name>
<surname>Karczewski</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Minikel</surname> <given-names>EV</given-names>
</name>
<name>
<surname>Samocha</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Banks</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fennell</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source>Nature</source>. (<year>2016</year>) <volume>536</volume>:<page-range>285&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature19057</pub-id>, PMID: <pub-id pub-id-type="pmid">27535533</pub-id></citation></ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>T&#xfc;ttelmann</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ruckert</surname> <given-names>C</given-names>
</name>
<name>
<surname>R&#xf6;pke</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Disorders of spermatogenesis: Perspectives for novel genetic diagnostics after 20 years of unchanged routine</article-title>. <source>Med Genet</source>. (<year>2018</year>) <volume>30</volume>:<fpage>12</fpage>&#x2013;<lpage>20</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11825-018-0181-7</pub-id>, PMID: <pub-id pub-id-type="pmid">29527098</pub-id></citation></ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krausz</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Male infertility: pathogenesis and clinical diagnosis</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source>. (<year>2011</year>) <volume>25</volume>:<page-range>271&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.beem.2010.08.006</pub-id>, PMID: <pub-id pub-id-type="pmid">21397198</pub-id></citation></ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krausz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Escamilla</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Chianese</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Genetics of male infertility: from research to clinic</article-title>. <source>Reproduction</source>. (<year>2015</year>) <volume>150</volume>:<page-range>R159&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1530/REP-15-0261</pub-id>, PMID: <pub-id pub-id-type="pmid">26447148</pub-id></citation></ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Metzler-Guillemain</surname> <given-names>C</given-names>
</name>
<name>
<surname>Toure</surname> <given-names>A</given-names>
</name>
<name>
<surname>Coutton</surname> <given-names>C</given-names>
</name>
<name>
<surname>Arnoult</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ray</surname> <given-names>PF</given-names>
</name>
</person-group>. <article-title>Single gene defects leading to sperm quantitative anomalies</article-title>. <source>Clin Genet</source>. (<year>2017</year>) <volume>91</volume>:<page-range>208&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cge.12900</pub-id>, PMID: <pub-id pub-id-type="pmid">27779755</pub-id></citation></ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olesen</surname> <given-names>IA</given-names>
</name>
<name>
<surname>Andersson</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Aksglaede</surname> <given-names>L</given-names>
</name>
<name>
<surname>Skakkebaek</surname> <given-names>NE</given-names>
</name>
<name>
<surname>Rajpert-de Meyts</surname> <given-names>E</given-names>
</name>
<name>
<surname>Joergensen</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical, genetic, biochemical, and testicular biopsy findings among 1,213 men evaluated for infertility</article-title>. <source>Fertil Steril</source>. (<year>2017</year>) <volume>107</volume>:<fpage>74</fpage>&#x2013;<lpage>82.e7</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.fertnstert.2016.09.015</pub-id>, PMID: <pub-id pub-id-type="pmid">27793385</pub-id></citation></ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punab</surname> <given-names>M</given-names>
</name>
<name>
<surname>Poolamets</surname> <given-names>O</given-names>
</name>
<name>
<surname>Paju</surname> <given-names>P</given-names>
</name>
<name>
<surname>Vihljajev</surname> <given-names>V</given-names>
</name>
<name>
<surname>Pomm</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ladva</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Causes of male infertility: a 9-year prospective monocentre study on 1737 patients with reduced total sperm counts</article-title>. <source>Hum Reprod</source>. (<year>2017</year>) <volume>32</volume>:<fpage>18</fpage>&#x2013;<lpage>31</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/humrep/dew284</pub-id>, PMID: <pub-id pub-id-type="pmid">27864361</pub-id></citation></ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourinaris</surname> <given-names>T</given-names>
</name>
<name>
<surname>Smedley</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cipriani</surname> <given-names>V</given-names>
</name>
<name>
<surname>Sheikh</surname> <given-names>I</given-names>
</name>
<name>
<surname>Athanasiou-Fragkouli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chinnery</surname> <given-names>P</given-names>
</name>
<etal/>. <collab>Genomics England Research Consortium</collab>
</person-group>. <article-title>Identification of UBAP1 mutations in juvenile hereditary spastic paraplegia in the 100,000 Genomes Project</article-title>. <source>Eur J Hum Genet</source>. (<year>2020</year>) <volume>28</volume>:<page-range>1763&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41431-020-00720-w</pub-id>, PMID: <pub-id pub-id-type="pmid">32934340</pub-id></citation></ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuvertino</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hartill</surname> <given-names>V</given-names>
</name>
<name>
<surname>Colyer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Garner</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nair</surname> <given-names>N</given-names>
</name>
<name>
<surname>Al-Gazali</surname> <given-names>L</given-names>
</name>
<etal/>. <collab>Genomics England Research Consortium</collab>
</person-group>. <article-title>A restricted spectrum of missense KMT2D variants cause a multiple malformations disorder distinct from Kabuki syndrome</article-title>. <source>Genet Med</source>. (<year>2020</year>) <volume>22</volume>:<page-range>867&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41436-019-0743-3</pub-id>, PMID: <pub-id pub-id-type="pmid">31949313</pub-id></citation></ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplanis</surname> <given-names>J</given-names>
</name>
<name>
<surname>Samocha</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Wiel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Arvai</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Eberhardt</surname> <given-names>RY</given-names>
</name>
<etal/>. <collab>Deciphering Developmental Disorders Study</collab>
</person-group>. <article-title>Evidence for 28 genetic disorders discovered by combining healthcare and research data</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>586</volume>:<page-range>757&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-020-2832-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33057194</pub-id></citation></ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>WL</given-names>
</name>
<name>
<surname>Tu</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>YQ</given-names>
</name>
</person-group>. <article-title>Insight on multiple morphological abnormalities of sperm flagella in male infertility: what is new</article-title>? <source>Asian J Androl</source>. (<year>2020</year>) <volume>22</volume>:<page-range>236&#x2013;45</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/aja.aja_53_19</pub-id>, PMID: <pub-id pub-id-type="pmid">31210147</pub-id></citation></ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knowles</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Zariwala</surname> <given-names>M</given-names>
</name>
<name>
<surname>Leigh</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Primary ciliary dyskinesia</article-title>. <source>Clin Chest Med</source>. (<year>2016</year>) <volume>37</volume>:<page-range>449&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccm.2016.04.008</pub-id>, PMID: <pub-id pub-id-type="pmid">27514592</pub-id></citation></ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goutaki</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maurer</surname> <given-names>E</given-names>
</name>
<name>
<surname>Halbeisen</surname> <given-names>FS</given-names>
</name>
<name>
<surname>Amirav</surname> <given-names>I</given-names>
</name>
<name>
<surname>Barbato</surname> <given-names>A</given-names>
</name>
<name>
<surname>Behan</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results</article-title>. <source>Eur Respir J</source>. (<year>2017</year>) <volume>49</volume>:<fpage>1601181</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1183/13993003.01181-2016</pub-id>, PMID: <pub-id pub-id-type="pmid">28052956</pub-id></citation></ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Diagnosis and management of children with primary ciliary dyskinesia</article-title>. <source>Nurs Child Young People</source>. (<year>2017</year>) <volume>29</volume>:<fpage>38</fpage>&#x2013;<lpage>47</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.7748/ncyp.2017.e93690</pub-id>
</citation></ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coutton</surname> <given-names>C</given-names>
</name>
<name>
<surname>Escoffier</surname> <given-names>J</given-names>
</name>
<name>
<surname>Martinez</surname> <given-names>G</given-names>
</name>
<name>
<surname>Arnoult</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ray</surname> <given-names>PF</given-names>
</name>
</person-group>. <article-title>Teratozoospermia: spotlight on the main genetic actors in the human</article-title>. <source>Hum Reprod Update</source>. (<year>2015</year>) <volume>21</volume>:<page-range>455&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/humupd/dmv020</pub-id>, PMID: <pub-id pub-id-type="pmid">25888788</pub-id></citation></ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chemes</surname> <given-names>HE</given-names>
</name>
<name>
<surname>Carizza</surname> <given-names>C</given-names>
</name>
<name>
<surname>Scarinci</surname> <given-names>F</given-names>
</name>
<name>
<surname>Brugo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Neuspiller</surname> <given-names>N</given-names>
</name>
<name>
<surname>Schwarsztein</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Lack of a head in human spermatozoa from sterile patients: a syndrome associated with impaired fertilization</article-title>. <source>Fertil Steril</source>. (<year>1987</year>) <volume>47</volume>:<page-range>310&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0015-0282(16)50011-9</pub-id>, PMID: <pub-id pub-id-type="pmid">3545911</pub-id></citation></ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<name>
<surname>Du</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Homozygous Loss of Septin12, but not its Haploinsufficiency, Leads to Male Infertility and Fertilization Failure</article-title>. <source>Front Cell Dev Biol</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>850052</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcell.2022.850052</pub-id>, PMID: <pub-id pub-id-type="pmid">35547809</pub-id></citation></ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hotaling</surname> <given-names>J</given-names>
</name>
<name>
<surname>Carrell</surname> <given-names>DT</given-names>
</name>
</person-group>. <article-title>Clinical genetic testing for male factor infertility: current applications and future directions</article-title>. <source>Andrology</source>. (<year>2014</year>) <volume>2</volume>:<page-range>339&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.2047-2927.2014.00200.x</pub-id>, PMID: <pub-id pub-id-type="pmid">24711280</pub-id></citation></ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelzman</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Genetic testing for men with infertility: techniques and indications</article-title>. <source>Transl Androl Urol</source>. (<year>2021</year>) <volume>10</volume>:<page-range>1354&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/tau-19-725</pub-id>, PMID: <pub-id pub-id-type="pmid">33850771</pub-id></citation></ref>
<ref id="B31">
<label>31</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Jungwirth</surname> <given-names>A</given-names>
</name>
<name>
<surname>Diemer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Dohle</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Diemer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kopa</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Dohle</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>European Association of Urology guidelines on Male Infertility: the 2019 update</article-title>. <source>Eur Urol</source>. (<year>2012</year>) <volume>62</volume>(<issue>2</issue>):<page-range>324&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.eururo.2012.04.048</pub-id>, PMID: <pub-id pub-id-type="pmid">22591628</pub-id></citation></ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skaletsky</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kuroda-Kawaguchi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Minx</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Cordum</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Hillier</surname> <given-names>L</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>LG</given-names>
</name>
<etal/>
</person-group>. <article-title>The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes</article-title>. <source>Nature</source>. (<year>2003</year>) <volume>423</volume>:<page-range>825&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature01722</pub-id>, PMID: <pub-id pub-id-type="pmid">12815422</pub-id></citation></ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colaco</surname> <given-names>S</given-names>
</name>
<name>
<surname>Modi</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Genetics of the human Y chromosome and its association with male infertility</article-title>. <source>Reprod Biol Endocrinol</source>. (<year>2018</year>) <volume>16</volume>:<fpage>14</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12958-018-0330-5</pub-id>, PMID: <pub-id pub-id-type="pmid">29454353</pub-id></citation></ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krausz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Degl&#x2019;Innocenti</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Y chromosome and male infertility:update, 2006</article-title>. <source>Front Biosci</source>. (<year>2006</year>) <volume>11</volume>:<page-range>3049&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2741/2032</pub-id>, PMID: <pub-id pub-id-type="pmid">16720375</pub-id></citation></ref>
<ref id="B35">
<label>35</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Salonia</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bettocchi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>J</given-names>
</name>
<name>
<surname>Capogrosso</surname> <given-names>P</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cilesiz</surname> <given-names>NC</given-names>
</name>
<etal/>
</person-group>. <article-title>European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction</article-title>. <source>Eur Urol</source>. (<year>2021</year>) <volume>80</volume>(<issue>3</issue>):<page-range>333&#x2013;57</page-range>. doi:<pub-id pub-id-type="doi">10.1016/j.eururo.2021.06.007</pub-id>, PMID: <pub-id pub-id-type="pmid">34183196</pub-id></citation></ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sosnay</surname> <given-names>PR</given-names>
</name>
<name>
<surname>Siklosi</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Van Goor</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kaniecki</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene</article-title>. <source>Nat Genet</source>. (<year>2013</year>) <volume>45</volume>:<page-range>1160&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ng.2745</pub-id>, PMID: <pub-id pub-id-type="pmid">23974870</pub-id></citation></ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ni</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis</article-title>. <source>Hum Reprod</source>. (<year>2012</year>) <volume>27</volume>:<fpage>25</fpage>&#x2013;<lpage>35</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/humrep/der377</pub-id>, PMID: <pub-id pub-id-type="pmid">22081250</pub-id></citation></ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghieh</surname> <given-names>F</given-names>
</name>
<name>
<surname>Barbotin</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Leroy</surname> <given-names>C</given-names>
</name>
<name>
<surname>Marcelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Swierkowsky-Blanchard</surname> <given-names>N</given-names>
</name>
<name>
<surname>Serazin</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Will whole-genome sequencing become the first-line genetic analysis for male infertility in the near future</article-title>? <source>Basic Clin Androl</source>. (<year>2021</year>) <volume>31</volume>:<elocation-id>21</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12610-021-00138-4</pub-id>, PMID: <pub-id pub-id-type="pmid">34407766</pub-id></citation></ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname> <given-names>TX</given-names>
</name>
<name>
<surname>Matzuk</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>Novel genes of the male reproductive system: potential roles in male reproduction and as non-hormonal male contraceptive targets</article-title>. <source>Mol Reprod Dev</source>. (<year>2024</year>) <volume>91</volume>:<fpage>e70000</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mrd.70000</pub-id>, PMID: <pub-id pub-id-type="pmid">39422082</pub-id></citation></ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedlazeck</surname> <given-names>FJ</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>H</given-names>
</name>
<name>
<surname>Darby</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Schatz</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Piercing the dark matter: bioinformatics of long-range sequencing and mapping</article-title>. <source>Nat Rev Genet</source>. (<year>2018</year>) <volume>19</volume>:<page-range>329&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41576-018-0003-4</pub-id>, PMID: <pub-id pub-id-type="pmid">29599501</pub-id></citation></ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhie</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nurk</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cechova</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hoyt</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Altemose</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>The complete sequence of a human Y chromosome</article-title>. <source>Nature</source>. (<year>2023</year>) <volume>621</volume>:<page-range>344&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-023-06457-y</pub-id>, PMID: <pub-id pub-id-type="pmid">37612512</pub-id></citation></ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oehler</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Wright</surname> <given-names>H</given-names>
</name>
<name>
<surname>Stark</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Mallett</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Schmitz</surname> <given-names>U</given-names>
</name>
</person-group>. <article-title>The application of long-read sequencing in clinical settings</article-title>. <source>Hum Genomics</source>. (<year>2023</year>) <volume>17</volume>:<fpage>73</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s40246-023-00522-3</pub-id>, PMID: <pub-id pub-id-type="pmid">37553611</pub-id></citation></ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>HQ</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>WZ</given-names>
</name>
</person-group>. <article-title>Application of CRISPR/cas technology in spermatogenesis research and male infertility treatment</article-title>. <source>Genes (Basel)</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1000</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/genes13061000</pub-id>, PMID: <pub-id pub-id-type="pmid">35741761</pub-id></citation></ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richer</surname> <given-names>G</given-names>
</name>
<name>
<surname>Goyvaerts</surname> <given-names>C</given-names>
</name>
<name>
<surname>Marchandise</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vanhaecke</surname> <given-names>T</given-names>
</name>
<name>
<surname>Goossens</surname> <given-names>E</given-names>
</name>
<name>
<surname>Baert</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Spermatogenesis in mouse testicular organoids with testis-specific architecture, improved germ cell survival and testosterone production</article-title>. <source>Biofabrication</source>. (<year>2024</year>) <volume>16</volume>(<issue>4</issue>). doi:&#xa0;<pub-id pub-id-type="doi">10.1088/1758-5090/ad618f</pub-id>, PMID: <pub-id pub-id-type="pmid">38986466</pub-id></citation></ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Human induced pluripotent stem cells and male infertility: an overview of current progress and perspectives</article-title>. <source>Hum Reprod</source>. (<year>2018</year>) <volume>33</volume>:<page-range>188&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/humrep/dex369</pub-id>, PMID: <pub-id pub-id-type="pmid">29315416</pub-id></citation></ref>
</ref-list>
</back>
</article>